LGND vs RPRX

For growth investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger pick with 27.

3% revenue growth year-over-year, versus 5. 1% for Royalty Pharma plc (RPRX). Royalty Pharma plc (RPRX) offers the better valuation at 28. 2x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate Ligand Pharmaceuticals Incorporated (LGND) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Royalty Pharma plc is actually cheaper at 10.

4x.

Over the past 5 years, Ligand Pharmaceuticals Incorporated (LGND) delivered a total return of +83.

9%, compared to +33. 3% for Royalty Pharma plc (RPRX). Over 10 years, the gap is even starker: LGND returned +95. 1% versus RPRX's +24. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Royalty Pharma plc (RPRX) is the lower-risk stock at 0.

45β versus Ligand Pharmaceuticals Incorporated's 0. 99β — meaning LGND is approximately 118% more volatile than RPRX relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 92% for Royalty Pharma plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ligand Pharmaceuticals Incorporated (LGND) is pulling ahead at 27.

3% versus 5. 1% for Royalty Pharma plc (RPRX). On earnings-per-share growth, the picture is similar: Royalty Pharma plc grew EPS 24. 1% year-over-year, compared to -107. 5% for Ligand Pharmaceuticals Incorporated. Over a 3-year CAGR, RPRX leads at 2. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Royalty Pharma plc (RPRX) is the more profitable company, earning 32.

4% net margin versus -2. 4% for Ligand Pharmaceuticals Incorporated — meaning it keeps 32. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RPRX leads at 65. 6% versus -13. 5% for LGND. At the gross margin level — before operating expenses — RPRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Royalty Pharma plc (RPRX) trades at 10.

4x forward P/E versus 26. 1x for Ligand Pharmaceuticals Incorporated — 15. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LGND: 15. 1% to $267. 75.

In this comparison, RPRX (1.

3% yield) pays a dividend. LGND does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Royalty Pharma plc (RPRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

45), 1. 3% yield). Both have compounded well over 10 years (RPRX: +24. 0%, LGND: +95. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LGND is a small-cap high-growth stock; RPRX is a mid-cap quality compounder stock. RPRX pays a dividend while LGND does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.